Cochrane · systematic review · CD012453
Topical and systemic antifungal therapy for chronic rhinosinusitis
Head, K, Sharp, S, Chong, LY, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
ENTAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
13
current version
GRADE rated
11
No studies
2
Included studies
NR
No studies 2 · 15.4%Ungraded 0 · 0%Very low 2 · 15.4%Low 9 · 69.2%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Topical antifungal versus placebo/no treatment for chronic rhinosinusitis
Population: chronic rhinosinusitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Heath‐related quality of life (HRQL) Topical antifungal vs placebo/no treatment | no estimate extracted | NR | Low Downgraded: imprecision |
Disease severity score Topical antifungal vs placebo/no treatment | no estimate extracted | NR | Very low Downgraded: imprecision, inconsistency, indirectness |
Generic HRQL (change from baseline) Topical antifungal vs placebo/no treatment | no estimate extracted | NR | Low Downgraded: imprecision, inconsistency, indirectness |
Generic HRQL (change from baseline) Topical antifungal vs placebo/no treatment | no estimate extracted | NR | Low Downgraded: imprecision, inconsistency, indirectness |
Adverse effects ‐ epistaxis Topical antifungal vs placebo/no treatment | RR 0.97 [0.14, 6.63] | NR | Low Downgraded: imprecision, inconsistency, indirectness |
Adverse effects ‐ headache Topical antifungal vs placebo/no treatment | RR 1.26 [0.6, 2.63] | NR | Very low Downgraded: imprecision, inconsistency, indirectness |
Adverse effects ‐ local irritation Topical antifungal vs placebo/no treatment | RR 2.29 [0.61, 8.62] | NR | Low Downgraded: imprecision, inconsistency, indirectness |
Systemic antifungal versus placebo/no treatment for chronic rhinosinusitis
Population: chronic rhinosinusitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Heath‐related quality of life (HRQL) Systemic antifungal vs placebo/no treatment | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision |
Disease severity score Systemic antifungal vs placebo/no treatment | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision |
Adverse effects ‐ hepatic toxicity Systemic antifungal vs placebo/no treatment | RR 3.35 [0.14, 78.6] | NR | Low Downgraded: risk of bias, imprecision |
Adverse effects ‐ gastrointestinal disturbances Systemic antifungal vs placebo/no treatment | RR 0.37 [0.04, 3.36] | NR | Low Downgraded: risk of bias, imprecision |
Adverse effects ‐ allergic reactions Systemic antifungal vs placebo/no treatment | no estimate extracted | NR | No studies |
Generic health‐related quality of life Systemic antifungal vs placebo/no treatment | no estimate extracted | NR | No studies |